<DrugInformationSummary id="CDR0000491901"><DrugInfoMetaData><DrugInfoType>Brief</DrugInfoType><DrugInfoAudience>Patients</DrugInfoAudience><DrugInfoDescription>This page contains brief information about cetuximab (Erbitux) and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.</DrugInfoDescription><DrugInfoURL xref="https://www.cancer.gov/about-cancer/treatment/drugs/cetuximab">Cetuximab</DrugInfoURL><FDAApproved>Yes</FDAApproved><TerminologyLink ref="CDR0000042384">cetuximab</TerminologyLink><GlossaryLink ref="CDR0000045467">cetuximab</GlossaryLink><USBrandNames><USBrandName>Erbitux</USBrandName></USBrandNames><PronunciationInfo><TermPronunciation>seh-TUK-sih-mab</TermPronunciation><MediaLink ref="CDR0000705501" type="audio/mpeg" alt="" language="en" id="_3"/><MediaLink ref="CDR0000705500" type="audio/mpeg" alt="" language="es" id="_4"/></PronunciationInfo><FDAExternalRef xref="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8bc6397e-4bd8-4d37-a007-a327e4da34d9&amp;audience=consumer">FDA label information for this drug is available at DailyMed.</FDAExternalRef></DrugInfoMetaData><DrugInfoTitle>Cetuximab</DrugInfoTitle><Section id="_FDA"><Para><ExternalRef xref="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8bc6397e-4bd8-4d37-a007-a327e4da34d9&amp;audience=consumer">FDA label information for this drug is available at DailyMed.</ExternalRef></Para></Section><Section id="_1"><Title>Use in Cancer</Title>                                                              
  <Para id="_2">Cetuximab is approved to be used alone or with other drugs to treat:</Para><ItemizedList Style="bullet" id="_10"><ListItem><Strong><GlossaryTermRef href="CDR0000444983" dictionary="Cancer.gov" audience="Patient">Colorectal cancer</GlossaryTermRef></Strong> that has spread to other parts of the body. It is used:<ItemizedList Style="bullet" id="_14"><ListItem>In patients whose cancer has the <GlossaryTermRef href="CDR0000044397" dictionary="Cancer.gov" audience="Patient">EGFR</GlossaryTermRef> <GlossaryTermRef href="CDR0000046092" dictionary="Cancer.gov" audience="Patient">protein</GlossaryTermRef> and the <GlossaryTermRef href="CDR0000785884" dictionary="Cancer.gov" audience="Patient">wild-type KRAS gene</GlossaryTermRef>.  It is used:<ItemizedList Style="bullet" id="_13"><ListItem>With <GlossaryTermRef href="CDR0000635807" dictionary="Cancer.gov" audience="Patient">FOLFIRI</GlossaryTermRef> <GlossaryTermRef href="CDR0000045650" dictionary="Cancer.gov" audience="Patient">combination chemotherapy</GlossaryTermRef> as the first treatment.</ListItem><ListItem>With <GlossaryTermRef href="CDR0000635811" dictionary="Cancer.gov" audience="Patient">irinotecan hydrochloride</GlossaryTermRef> in patients whose cancer was treated with chemotherapy that included irinotecan hydrochloride but it did not work or is no longer working.</ListItem><ListItem>Alone in patients whose cancer did not respond to <GlossaryTermRef href="CDR0000045465" dictionary="Cancer.gov" audience="Patient">oxaliplatin</GlossaryTermRef> and irinotecan hydrochloride or who cannot be treated with irinotecan hydrochloride.</ListItem></ItemizedList></ListItem><ListItem>In adults whose cancer has a  certain mutation in the <GeneName><GlossaryTermRef href="CDR0000561325" dictionary="Cancer.gov" audience="Patient">BRAF</GlossaryTermRef></GeneName> gene. It is given with <GlossaryTermRef href="CDR0000793869" dictionary="Cancer.gov" audience="Patient">encorafenib</GlossaryTermRef>.</ListItem></ItemizedList></ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000597171" dictionary="Cancer.gov" audience="Patient">Squamous cell carcinoma of the head and neck</GlossaryTermRef>.</Strong> It is used:<ItemizedList Style="bullet" id="_12"><ListItem>With <GlossaryTermRef href="CDR0000044971" dictionary="Cancer.gov" audience="Patient">radiation therapy</GlossaryTermRef> in  patients with <GlossaryTermRef href="CDR0000045955" dictionary="Cancer.gov" audience="Patient">locally</GlossaryTermRef> or regionally <GlossaryTermRef href="CDR0000478743" dictionary="Cancer.gov" audience="Patient">advanced</GlossaryTermRef> cancer.</ListItem><ListItem>With <GlossaryTermRef href="CDR0000045841" dictionary="Cancer.gov" audience="Patient">platinum</GlossaryTermRef> chemotherapy and <GlossaryTermRef href="CDR0000046090" dictionary="Cancer.gov" audience="Patient">fluorouracil</GlossaryTermRef> in patients with locally or regionally recurrent cancer  or <GlossaryTermRef href="CDR0000044058" dictionary="Cancer.gov" audience="Patient">metastatic</GlossaryTermRef> cancer.</ListItem><ListItem>Alone in patients with recurrent or metastatic cancer that got worse after platinum chemotherapy.</ListItem></ItemizedList></ListItem></ItemizedList><Para id="_11">Cetuximab is also being studied in the treatment of other types of cancer.</Para>                          
 </Section><Section id="_About"><Title>More About Cetuximab</Title><Para id="_Dict_1"><ExternalRef xref="https://www.cancer.gov/publications/dictionaries/cancer-drug/def/42384">Definition from the NCI Drug Dictionary</ExternalRef> - Detailed scientific definition and other names for this drug.</Para>

<Para id="_About_8.40">MedlinePlus Information on <ExternalRef xref="https://medlineplus.gov/druginfo/meds/a607041.html">Cetuximab</ExternalRef> - A lay language summary of important information about this drug that may include the following:</Para>
<ItemizedList Style="bullet" id="_About_9.41"><ListItem>warnings about this drug,</ListItem><ListItem>what this drug is used for and how it is used,</ListItem><ListItem>what you should tell your doctor before using this drug,</ListItem><ListItem>what you should know about this drug before using it, </ListItem><ListItem>other drugs that may interact with this drug, and</ListItem><ListItem>possible side effects.  </ListItem></ItemizedList><Para id="_About_10.42">Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for.  This patient information sheet applies only to approved uses of the drug.  However, much of the information may also apply to unapproved uses that are being studied.</Para></Section><Section id="_Research"><Title>Research Results and Related Resources</Title><Para><ExternalRef xref="https://www.cancer.gov/news-events/cancer-currents-blog/2024/head-neck-cancer-cetuximab-versus-durvalumab">Cetuximab Outperforms Durvalumab for Head and Neck Cancer When Cisplatin Isnâ€™t an Option</ExternalRef></Para><Para><ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies">Targeted Therapies to Treat Cancer</ExternalRef></Para><Para><ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/monoclonal-antibodies">Monoclonal Antibodies</ExternalRef></Para></Section><Section id="_ClinicalTrial_1"><Title>Clinical Trials Accepting Patients</Title><Para id="_ClinicalTrial_2"><ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials/intervention/C1723">Find Clinical Trials for Cetuximab</ExternalRef> - Check for trials from NCI's list of cancer clinical trials now accepting patients.</Para></Section> 
  <DrugInfoDisclaimer>


<Para id="_Disclaimer_4"><Strong>Important: </Strong>The drug information on this page is meant to be educational. It is not a substitute for medical advice. The information may not cover all possible uses, actions, interactions, or side effects of this drug, or precautions to be taken while using it. Please see your health care professional for more information about your specific medical condition and the use of this drug.
</Para></DrugInfoDisclaimer> 
  <DateFirstPublished>2006-10-05</DateFirstPublished><DateLastModified>2024-12-19</DateLastModified></DrugInformationSummary>
